Medicines Discovery Catapult

PACE has launched its second funding round, with up to £5 million available to support cutting-edge diagnostic projects. This funding is part of a broader £30 million investment to address the global challenge of AMR.

A new total-body PET scanner that is quicker for the patient and produces higher quality images for faster and earlier diagnosis and treatment of illnesses like cancer and heart conditions, was unveiled by Ministers in London yesterday (Wednesday 27 November).

United Kingdom National Nuclear Laboratory and Medicines Discovery Catapult have received funding to drive the development of innovative approaches for new cancer treatments.

Medicines Discovery Catapult (MDC), a national Life Sciences service dedicated to driving productivity and impact in drug R&D, has strengthened its Executive team with the appointment of a Chief Commercial Officer and its first Managing Director.

PACE (Pathways to Antimicrobial Clinical Efficacy) has today launched its second funding round with up to £5 million available to support cutting-edge diagnostic projects. This funding is part of a broader £30 million investment to address the global challenge of antimicrobial resistance (AMR).

ERS Genomics Limited (ERS), the CRISPR licensing Company, and Medicines Discovery Catapult (MDC), an independent, not-for-profit drug discovery innovation centre, have signed a non-exclusive commercial-use CRISPR license agreement. The partnership combines ERS’s CRISPR/Cas9 patent portfolio with MDC’s world-class expertise and technology.

The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate has today announced the first cohort of awardees of its Collaborative Discovery Programme (CDP) funding.